ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Gu-Ben-Hua-Shi (AESS) formula ameliorates atopic dermatitis via regulating NLRP3 signaling pathways

Li, Xiong; Feng, Luyao; Zhong, Tingjing; Mo, Xiumei; Wang, Dong; Gu, Jiangyong; Chen, Dacan*; Zeng, Xing; Yan, Fenggen*广东省人民医院; 广州中医药大学
SAUDI PHARMACEUTICAL JOURNAL2023-11DOI: 10.1016/j.jsps.2023.101792
26阅读
引用收藏
分享

摘要

Background: Gu-ben-hua-shi (AESS) formula is a clinical experienced prescription from Guangdong Hospital of Traditional Chinese Medicine (TCM), which is used to treat atopic dermatitis (AD). Our previ-ous work has shown that AESS has therapeutic effect on AD by regulating yes-associated protein (YAP). AESS formula has multi-component and multi-target characteristic, and need to be analyzed by system-atic chemical profiling and network pharmacology technology, as well as verification of key signaling pathways. Therefore, this study aimed at investigating the efficacy and effect of AESS formula in the treat-ment of AD and its effect on NLRP3 signaling pathway.Methods: The components of AESS formula were analyzed and identified by ultra high performance liq-uid chromatography/tandem mass spectrometry (UHPLC-MS/MS), and the potential mechanism of AESS formula in the treatment of AD was predicted by network pharmacology approach, with detected main components, and the potential components targeted NOD-like receptor thermal protein domain associ-ated protein (NLRP3) signaling pathway [Direct binding with NLRP3, apoptosis-associated speck-like pro-tein (ASC) and Caspase-1] were assessed using molecular docking. AD-like symptoms were constructed by DNCB induced BALB/c mice. The effect of AESS formula on dorsal skin structure in AD-like mice was observed using H&E staining. Furthermore, the western blotting experiment explored the expression of the NLRP3 pathway protein.Results: By UHPLC-MS/MS analysis, 91 compounds were detected in AESS formula, and 76 of them were identified, while by network pharmacological analysis, 1500 component targets were obtained, and 257 of them were obtained by intersection with eczema targets. Then one of the key pathways, nucleotide-binding oligomerization domain (NOD)-like signaling pathway was obtained by KEGG enrichment anal-ysis. Molecular docking results showed 24 main components could effectively combine with ASC and Caspase-1 (<= -7 kcal/mol). The animal experiment results further showed that AESS formula alleviates symptoms in AD-like mice. ELISA kit results showed that the expression of IL-1B and IL-18 in serum was inhibited after AESS treatment. Additionally, western blotting analysis showed that the expressions of ASC, Caspase-1 and NLRP3 protein expression in the skin tissue of mice were down-regulated after AESS treatment. The experimental results show that AESS formula inhibited the expression of NLRP3 sig-naling pathway for the treatment of AD.Conclusions: AESS formula can improve AD symptoms in mice by inhibiting the activation of NLRP3 inflammasome and the expression of the related downstream inflammatory cytokines.

学科与关键词

关键词
Atopic dermatitisTraditional Chinese medicineUHPLC-MS/MSNLRP3 signaling pathway
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
SAUDI PHARMACEUTICAL JOURNAL
发表日期
2023-11
卷期
第 31 卷, 第 11 期
页码
101792
DOI
10.1016/j.jsps.2023.101792
语言
ENGLISH
成果收录
SCIE
资助标注
National Natural Science Foundation of China Youth Fund [82004364]; Second Affiliated Hospital of Guangzhou University of Chinese Medicine [SZ2021ZZ17, SZ2021ZZ39]; Guangdong-Hong Kong-Macau Joint Laboratory on Chinese Medicine and Immune Disease Research, Guangzhou University of Chinese Medicine [2020B1212030006]; Guangdong Provincial Key Laboratory of Chinese Medicine for Prevention and Treatment of Refractory Chronic Diseases [2018B030322012, MB2020KF04]; Guangzhou Science and Technology Plan Project - Municipal School (College) joint funding project [202201020333]; Municipal Schools (Colleges) jointly funded projects [SL2024A03J00887]; Key-Area Research and Development Program of Guangdong Province [2020B1111100010]

作者

  • L

    Li, Xiong (第一作者)

    2 · guangzhou univ chinese med

  • F

    Feng, Luyao

    shenyang pharmaceut univ

查看全部 9 位作者收起作者
  • Z

    Zhong, Tingjing

    2 · guangzhou univ chinese med

  • M

    Mo, Xiumei

    2 · guangdong prov hosp · guangzhou univ chinese med

  • W

    Wang, Dong

    shenyang pharmaceut univ

  • G

    Gu, Jiangyong

    guangzhou univ chinese med

  • C

    Chen, Dacan (通讯)

    2 · guangdong prov hosp · guangzhou univ chinese med

  • Z

    Zeng, Xing

    2 · guangzhou univ chinese med

  • Y

    Yan, Fenggen (通讯)

    2 · guangdong prov hosp · guangzhou univ chinese med

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417